Guardant Health acquires Guardant Health AMEA, Inc. (SoftBank joint-venture buyout)

Guardant Health acquired Guardant Health AMEA, Inc. (SoftBank joint-venture buyout) for approximately $177.8 million, a transaction completed in June 2022, structured as all cash.

Guardant Health AMEA, Inc. (SoftBank joint-venture buyout) operates in International precision oncology commercialization (Asia, Middle East and Africa), is based in Asia, Middle East and Africa (41 countries); near-term focus on Japan. Guardant purchased all of the remaining shares of Guardant Health AMEA, Inc. held by SoftBank (SVF Excalibur (Cayman) Limited) and its affiliates, giving Guardant full control over its liquid-biopsy operations across the Asia, Middle East and Africa region. The AMEA entity, established in May 2018 as a joint venture between Guardant Health and the SoftBank Vision Fund, serves 41 countries across the region. The purchase price of $177.8 million was determined based on an independent third-party valuation, and the joint venture agreement was terminated concurrently with the closing.

By acquiring the remaining shares of Guardant Health AMEA, we can focus on creating a unified and centralized global organization that delivers on our promise to help conquer cancer and improve patient outcomes.

More than half of the world's estimated new cancer cases come from Asia, the Middle East and Africa, and full ownership lets Guardant directly accelerate adoption of its blood-based cancer tests across the region. Unified, centralized global organization; direct control of regional commercialization rather than via a jointly governed entity. Operations folded into Guardant Health's consolidated global organization (the AMEA region).

Advisory firms were not disclosed for this transaction.